IQVIA (NYSE:IQV) Coverage Initiated by Analysts at HSBC

HSBC initiated coverage on shares of IQVIA (NYSE:IQV) in a research note issued to investors on Wednesday, MarketBeat.com reports. The brokerage issued a buy rating and a $260.00 price objective on the medical research company’s stock.

Several other equities research analysts also recently commented on the stock. Truist Financial boosted their target price on shares of IQVIA from $244.00 to $260.00 and gave the company a buy rating in a research note on Tuesday, July 18th. Citigroup boosted their target price on shares of IQVIA from $200.00 to $225.00 and gave the company a neutral rating in a research note on Wednesday, August 2nd. Stifel Nicolaus boosted their target price on shares of IQVIA from $255.00 to $281.00 and gave the company a buy rating in a research note on Wednesday, August 2nd. StockNews.com started coverage on shares of IQVIA in a research note on Thursday, August 17th. They issued a hold rating on the stock. Finally, Barclays upped their price target on shares of IQVIA from $230.00 to $250.00 in a research report on Tuesday, June 27th. Two analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. According to MarketBeat.com, the company has an average rating of Moderate Buy and an average target price of $252.00.

IQVIA Stock Down 0.9 %

IQV opened at $218.81 on Wednesday. IQVIA has a fifty-two week low of $165.75 and a fifty-two week high of $241.86. The company has a debt-to-equity ratio of 2.16, a current ratio of 0.81 and a quick ratio of 0.81. The firm’s fifty day moving average price is $220.87 and its two-hundred day moving average price is $207.95. The company has a market capitalization of $40.07 billion, a P/E ratio of 37.66, a P/E/G ratio of 2.27 and a beta of 1.37.

IQVIA (NYSE:IQV) last posted its quarterly earnings results on Tuesday, August 1st. The medical research company reported $2.22 earnings per share for the quarter, topping analysts’ consensus estimates of $2.09 by $0.13. IQVIA had a net margin of 7.47% and a return on equity of 30.14%. The firm had revenue of $3.73 billion for the quarter, compared to the consensus estimate of $3.70 billion. On average, analysts anticipate that IQVIA will post 9.21 EPS for the current year.

Institutional Trading of IQVIA

Institutional investors and hedge funds have recently modified their holdings of the stock. Dimensional Fund Advisors LP increased its stake in shares of IQVIA by 17.8% in the 4th quarter. Dimensional Fund Advisors LP now owns 787,977 shares of the medical research company’s stock valued at $161,455,000 after acquiring an additional 118,951 shares during the last quarter. Mitsubishi UFJ Trust & Banking Corp grew its position in shares of IQVIA by 0.7% in the 1st quarter. Mitsubishi UFJ Trust & Banking Corp now owns 112,697 shares of the medical research company’s stock valued at $22,414,000 after purchasing an additional 810 shares during the period. Mn Services Vermogensbeheer B.V. grew its position in shares of IQVIA by 3.2% in the 1st quarter. Mn Services Vermogensbeheer B.V. now owns 94,100 shares of the medical research company’s stock valued at $18,716,000 after purchasing an additional 2,900 shares during the period. Element Capital Management LLC acquired a new position in shares of IQVIA in the 1st quarter valued at approximately $4,824,000. Finally, Gradient Investments LLC grew its position in shares of IQVIA by 23.9% in the 1st quarter. Gradient Investments LLC now owns 57,926 shares of the medical research company’s stock valued at $11,521,000 after purchasing an additional 11,163 shares during the period. 86.82% of the stock is owned by institutional investors.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.